Akademik Veri Yönetim Sistemi
43rd Congress of the International Society of Urology (SIU), İstanbul, Türkiye, 11 - 14 Ekim 2023, ss.106
Background/aim:
The aim of this study was to assess the long-term clinical efficacy of
temporary Bulbar urethral stent (BUS) used for the treatment of recurrent bulbar
urethral stricture (US).
Materials and Methods:
A total of 187 patients with recurrent bulbar US who underwent BUS placement
after internal urethrotomy between 2009 and 2021 were enrolled. An indwelling
time of 12 months was planned for the stents. After stent removal, the criteria
for success of BUS treatment were defined as follows: no evidence of stricture
on urethrogram or endoscopy; more than 15 mL/s of urinary peak flow; and no
recurrent urinary tract infections. Patients were divided into 2 groups based
on clinical success and compared.
Results: The mean
age, US length, and indwelling time were 47.3 (±8.2) years, 2.3 (±0.4) cm, 9.9
(±2.2) months, respectively. Median (range) follow-up was 71 (7-88) months.
Clinical success was achieved in 79.1% patients. Longer indwelling time 88.4%
vs 62% months and US lenght <2 cm(87.9% [<2 cm] vs. 67.4% [≥2 cm] were
significantly associated with clinical success (p<0.05).
Conclusion: This
study is both the largest patient series and longest follow-up for BUS for
bulbar US. Our results suggest that BUS is safe, easy and minimally invasive
treatment alternative for recurrent bulbar US.